exclusion criteria – Page 19 – Communicable Diseases Research

A multi-center, randomized controlled trial by the Integrative Management in Japan for Epidemic Disease (IMJEDI study-RCT) on the use of Kampo medicine, kakkonto with shosaikotokakikyosekko, in mild-to-moderate COVID-19 patients for symptomatic relief and prevention of severe stage: a structured summary of a study protocol for a randomized controlled trial

Letter

Published on 2020-10-022022-10-29
Journal: Trials [Category] COVID-19, MERS, SARS,

Engineered tissues and strategies to overcome challenges in drug development

Review article

Published on 2020-09-262022-10-05
Journal: Advanced drug delivery reviews [Category] 비임상,

Etiology and antimicrobial resistance of secondary bacterial infections in patients hospitalized with COVID-19 in Wuhan, China: a retrospective analysis

Research

Published on 2020-09-222022-10-28
Journal: Antimicrobial Resistance and Infection Control [Category] COVID-19, SARS,

[키워드] Admission antimicrobial resistance applied Bacteria Clinical course collected coronavirus disease COVID-19 Critical demographic died electronic medical record enrolled etiology examined exclusion criteria Gram-negative bacteria high mortality Hospitalization Hospitalized incidence Inclusion Infection Isolation Meticillin occur Patient patients hospitalized pneumoniae proportion reported Result Retrospective analysis Retrospective study secondary bacterial infection Secondary bacterial infections severe patients severity single-center Staphylococcus aureus strain the patient therapy Union Hospital with COVID-19 Wuhan
[DOI] 10.1186/s13756-020-00819-1 PMC 바로가기 [Article Type] Research

Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial

Letter

Published on 2020-09-092022-10-29
Journal: Trials [Category] Coronavirus, SARS,

[키워드] 24 hour 7-point ordinal scale absence addition administration Admission ALT anticipated assigned AST baseline biological parameters candidate Care clinical Clinical research clinical status clinical trial clinician Comorbidity conditions Control control arm control group Coronavirus infections Council COVID 19 COVID-19 COVID-19 infection criteria current D-dimer Day death rate decrease discharge dissemination dose drug Duration early stage Efficacy element ELISA enrolment EudraCT European evaluate exclusion criteria exploratory extracorporeal membrane oxygenation Frame harmonization hospitalisation hospitalised hospitalised patient hyperinflammatory status hypersensitivity Hypothesis identify IL-6 IL-6 levels IL-6 receptor inhibitors IL-6R In-hospital incidence Inclusion inclusion criteria independent Infection Informed inhibitor interstitial pneumonia Intervention intervention group intestinal perforation Invasive mechanical ventilation investigator investigator-initiated lactation Local marker measure mechanical ventilation moderate moderate-severe neutrophil count Non-invasive non-invasive ventilation number number of death objective Open label trial outbreak outcome oxygen Oxygenation pandemic participant pathogen patients treated performed Platelet Pneumonia positive positive RT-PCR Positive test Prednisone Presence Prevent progression protocol random randomisation randomised randomised controlled trial receive recruited recruitment Registered reported requiring supplemental oxygen responsible routine clinical practice RT-PCR SAEs Sample size sarilumab SARS-CoV-2 SARS-COV-2 infection score Sepsis Serious Adverse Event serum Severe COVID-19 Infection single center single dose Spain Standard Standard of care status Study protocol Subcutaneous subcutaneous injection the patient therapy treated Treatment treatment arm treatment with tocilizumab Trial ULN union unit verbal website
[DOI] 10.1186/s13063-020-04588-5 PMC 바로가기 [Article Type] Letter

Anticoagulation in critically ill patients on mechanical ventilation suffering from COVID-19 disease, The ANTI-CO trial: A structured summary of a study protocol for a randomised controlled trial

COVID-19 질병으로 고통받는 중환자의 기계적 환기에 대한 항응고, The ANTI-CO 시험: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약

Letter

Published on 2020-09-072022-08-13
Journal: Trials [Category] SARS, 임상,

[키워드] 1:1 Abnormalities Administered allergic Anti-Co trial Anticoagulant anticoagulation anticoagulation treatment approval aPTT assumed attending physicians bivalirudin blinded Blinding Clinical improvement Coagulation comparator control group Controlled trial Corporation COVID-19 COVID-19 disease Critically ill patient D-dimer D-dimers dissemination distress dose dropout drug element eligibility eligible exclusion criteria expected experimental group FiO2 for inclusion groups heparin ICU IMPROVE include Inclusion inclusion criteria intervention group intravenously Invasive mechanical ventilation limit Local mechanical ventilation normally distributed number objective on mechanical ventilation outcome P/F P/F ratio PaO2 paO2/fiO2 parallel group parameter participant Patient patients patients with COVID-19 performed Physicians positive power power of 80% Pregnancy Primary outcome protocol randomised randomised controlled trial randomization Randomized receive recruitment Registered registration number respiratory distress Respiratory failure Sample size sample size calculation screened standard treatment status study drug Study protocol subcutaneously subject Taking the mean the patient thrombosis title treated Treatment treatment group Trial registration website
[DOI] 10.1186/s13063-020-04689-1 PMC 바로가기 [Article Type] Letter

Quality Assessment of the Chinese Clinical Trial Protocols Regarding Treatments for Coronavirus Disease 2019

Pharmacology

Published on 2020-08-272022-10-31
Journal: Frontiers in Pharmacology [Category] COVID-19,

[키워드] 2019 novel coronavirus allocation concealment assessment autonomous baseline China Chinese clinical clinical trial clinically conducted coronavirus disease Coronavirus disease 2019 COVID-19 cross-sectional analysis description effective Effectiveness Efficacy and safety eligibility criteria evaluate exclusion criteria finding high risk indicated Intervention investigator knowledge majority Medicine Methodological quality methodology ongoing trial Open-label outcome measures patients with COVID-19 Potential treatment protocol protocols Quality random Randomized controlled trial Randomized Controlled Trial protocol RCT recruitment regions registry remained Result risk robust screened selection bia sequence Spread Standard study inclusion subject Therapies therapy translation Treatment treatments for COVID-19 Trial trial protocol
[DOI] 10.3389/fphar.2020.01330 PMC 바로가기 [Article Type] Pharmacology

High dose dexamethasone treatment for Acute Respiratory Distress Syndrome secondary to COVID-19: a structured summary of a study protocol for a randomised controlled trial

COVID-19에 따른 급성 호흡곤란 증후군에 대한 고용량 덱사메타손 치료: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약

Letter

Published on 2020-08-262022-08-13
Journal: Trials [Category] MERS, 임상,

[키워드] 1:1 active cancer acute respiratory distress acute respiratory distress syndrome Adult patients advance directives Advanced cancer age alpha error anticipated approved ARDS assessment assigned bilateral pulmonary infiltrates Blinding block breast-feeding Buenos Aires capture cardiac disease CEMIC clinical clinical trial code Complete concealed Confirmed COVID-19 COVID-19, Dexamethasone, Acute Respiratory Distress Syndrome, Randomised controlled trial, protocol, Steroids delirium develop Dexamethasone diagnosis of SARS-CoV-2 directive discharge disease dissemination do not resuscitate dose Effectiveness element End-Expiratory Pressure evaluate exclusion criteria Expiratory Pressure explained failure followed by Frequency glucocorticoid Glucocorticoids group hemodynamic High dose HIV infection hypoxemic Hypoxemic respiratory failure ICU Immunosuppression Immunosuppressive agents include inclusion criteria Infection Informed consent intensive care unit International legal guardian Length less Life expectancy local Ethics Committee mechanical ventilation Mortality multicenter muscle weakness Nosocomial infection Nosocomial infections number objective open open label open trial other disease other diseases outcome Palliative care PaO parallel group participant Participation Patient Patient care platform Pneumonia Positive end-expiratory pressure power power of 80% Prednisone pressure Prone position protocol R language random randomised randomised controlled trial randomization Randomized randomized clinical trial receive recruitment Registered renal renal disease respiratory respiratory distress Respiratory distress syndrome Respiratory failure resuscitate order RT-PCR Sample size SARS-COV-2 infection SARS-CoV-2 pneumonia secondary Secondary outcomes secondary to sequence Sequential Organ Failure Assessment severe immunosuppression SOFA Standard deviation status Stratified randomization Study protocol subject Support syndrome table terminal Terminal disease title Treatment treatment groups Trial Trial registration two-tailed alpha error Variation ventilator ventilator-free day Ventilator-free days ventilatory Version viral shedding weakness website women
[DOI] 10.1186/s13063-020-04646-y PMC 바로가기 [Article Type] Letter

The effect of prostacyclin (Iloprost) infusion at a dose of 1 ng/kg/min for 72 hours compared to placebo in mechanically ventilated patients with COVID-19: A structured summary of a study protocol for a randomized controlled trial

인공호흡기를 사용하는 COVID-19 환자에서 위약과 비교하여 72시간 동안 1ng/kg/min 용량의 프로스타사이클린(일로프로스트) 주입 효과: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약

Letter

Published on 2020-08-262022-08-13
Journal: Trials [Category] MERS, 임상,

[키워드] (Iloprost (normal saline) 1:1 Acute coronary syndrome Adult patient Adult patients age anticipated Biomarker bleeding blinded Blinding block can not Capital Capital Region capture Clinicians comparator concealed conducted Confirmed Confirmed COVID-19 infection Consent coronary syndrome COVID-19 COVID-19 infection COVID-19 patients criteria Day defined Denmark dissemination dose element endothelial endotheliopathy EudraCT exclusion criteria exploratory facilitate FIVE heart failure Hvidovre Hospital hypersensitivity Iloprost intensive care unit intensive care units investigators Local mechanical ventilation mechanically ventilated mechanically ventilated COVID-19 patients mechanically ventilated patient multicenter normal saline number objective outcome parallel group participant Patient patients performed Placebo Pregnancy primary endpoint prostacyclin protocol randomisation randomised Randomized Randomized controlled trial recruitment REDCap Region Sample size sequence statisticians status stratified Study protocol Suspected thrombomodulin total sample size Trial Urine website Withdrawal
[DOI] 10.1186/s13063-020-04696-2 PMC 바로가기 [Article Type] Letter

A Meta-Analysis on the Effects of Hydroxychloroquine on COVID-19

Internal Medicine

Published on 2020-08-242022-10-31
Journal: Cureus [Category] COVID-19,

[키워드] acute respiratory syndrome adhere adverse effect Analysis analyzed article Azithromycin Chloroquine Clinical outcome Cochrane Library control group coronavirus COVID-19 disease disease severity Effect effort eligibility criteria eligible exclusion criteria Google Scholar greater group HCQ Healthcare professional Hydroxychloroquine Inclusion independent item Meta-analysis Mild moderate mortality rate outcome measure overall mortality pandemic participant patients with COVID-19 Prevent public health crisis Reporting review SARS-CoV-2 screened selected Side effect Spread Symptom Transmission treat treated treated patient virus was performed WHO World Health Organization
[DOI] 10.7759/cureus.10005 PMC 바로가기 [Article Type] Internal Medicine

Multi-centre, three arm, randomized controlled trial on the use of methylprednisolone and unfractionated heparin in critically ill ventilated patients with pneumonia from SARS-CoV-2 infection: A structured summary of a study protocol for a randomised controlled trial

Letter

Published on 2020-08-172022-10-29
Journal: Trials [Category] Coronavirus, MERS,

[키워드] 24 hour absolute reduction Administered administration AIFA airway allocation sequence Alpha Anticoagulant anticoagulant therapy Anticoagulant treatment approval Arm Aspergillus assigned assumption average bleeding bleeding event blinded Block randomisation block size BMI Brain Breastfeeding Candida checked childbearing age chronic clinical clinical condition clinically combined use conjunctival contributed corpus Corticosteroid COVID-19 criteria Critical Critically ill cytomegalovirus D-dimer level death defined Delay detect diagnostic discharge dissemination dosage drug dysfunction effective element eligible patient enoxaparin enrolled EudraCT exclusion criteria expected hematemesis hematoma heparin-induced thrombocytopenia Herpe high risk High-dose history hospital hospital discharge Hypothesis ICU ICU free day ICU Patients impairing Inclusion inclusion criteria indicated Infection initial Inpatient intensive care unit interval Intervention Intra-articular intramuscular intravenously invasive Invasive mechanical ventilation investigator Italian limit LMWH low molecular weight low-molecular weight heparin macroscopic major bleeding mechanical ventilation medical intervention Methylprednisolone Mortality mortality rate Myocardial Non-invasive non-invasive ventilation number objective occur ophthalmic organ dysfunction PaO parallel group participant Patient performed Pharyngeal swab Pneumonia positive positive pressure pregnancy test Presence Prophylactic prophylactic dose Prophylaxis protocol random randomisation randomised randomised controlled trial randomization Randomized Randomized controlled trial Randomly Ratio receive recent recruited recruitment Rectal Bleeding red blood cell reduce reducing Registered required risk of death Safety Sample size SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 pneumonia secondary secure severe disease sick significantly sodium status steroid stratified stroke study drug Study protocol subcutaneously surgical syndrome therapeutic therapeutic doses therapy Treatment treatment group unfractionated heparin Venous Thromboembolism ventilated patient Ventilation website Weighting Withdrawal women
[DOI] 10.1186/s13063-020-04645-z PMC 바로가기 [Article Type] Letter